
Sign up to save your podcasts
Or


For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/XRT865. CME/NCPD credit will be available until April 25, 2026.
The Good, the Bad, and the GVHD: Leveraging Modern Therapeutics to Improve Post-Transplant Outcomes
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by educational grants from Incyte Corporation, Mallinckrodt Pharmaceuticals, and Mesoblast Inc.
Disclosure information is available at the beginning of the video presentation.
By PVI, PeerView Institute for Medical Education4.1
2525 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/XRT865. CME/NCPD credit will be available until April 25, 2026.
The Good, the Bad, and the GVHD: Leveraging Modern Therapeutics to Improve Post-Transplant Outcomes
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by educational grants from Incyte Corporation, Mallinckrodt Pharmaceuticals, and Mesoblast Inc.
Disclosure information is available at the beginning of the video presentation.

43,566 Listeners

135 Listeners

318 Listeners

697 Listeners

497 Listeners

28 Listeners

10 Listeners

1,382 Listeners

5 Listeners

10 Listeners

4 Listeners

2 Listeners

5 Listeners

2 Listeners

3 Listeners

5 Listeners

5 Listeners

2 Listeners

0 Listeners

9 Listeners

2 Listeners

11 Listeners

2 Listeners

4 Listeners

3 Listeners

5 Listeners

290 Listeners

263 Listeners

3,339 Listeners

1,151 Listeners

195 Listeners

85 Listeners

512 Listeners

364 Listeners

430 Listeners